Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Sana Biotechnology, Inc. (SANA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted allogeneic hypoimmune-modified islet cells evade rejection and control glucose without immunosuppression or insulin treatment in non-human primate diabetes study Data published in Science Translational Medicine, Natur..."
05/08/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year"
03/16/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Announced SC291 IND clearance with goal to report initial clinical data this year"
08/04/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/16/2022 8-K Quarterly results
Docs: "Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates Plans to present data at multiple scientific conferences in 2022"
11/08/2021 8-K Quarterly results
Docs: "Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million"
08/04/2021 8-K Quarterly results
Docs: "Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression at ISSCR 2021"
05/05/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy